The benefit of early-stage diagnosis: A registry-based survey evaluating the quality of life in patients with melanoma.
Journal
Skin health and disease
ISSN: 2690-442X
Titre abrégé: Skin Health Dis
Pays: England
ID NLM: 9918227353706676
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
22
02
2023
revised:
29
03
2023
accepted:
06
04
2023
medline:
4
8
2023
pubmed:
4
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
The morbidity associated with advanced stage melanoma is an important consideration in the dialog surrounding early detection and overdiagnosis. Few studies have stratified melanoma patient quality of life (QoL) by stage at diagnosis. We sought to investigate if melanoma stage is independently associated with changes in QoL within a large, community-based melanoma registry. Secondarily, we investigated whether demographic factors such as age, geographic location or level of education are associated with changes in QoL in the same population. 1108 melanoma patients were surveyed over a three-month period using the QoL in Adult Cancer Survivors Survey, consisting of 47 items on a 7-point frequency scale. Data were analysed using both descriptive statistical models and adjusted multivariate logistic regression. There were 677 respondents generating a 61% response rate. Overall, higher stage at diagnosis correlated with the largest decreases in QoL as it pertained to both general ( Earlier stage at melanoma diagnosis is associated with better QoL and thus represents a crucial intervention in patient care. Given our findings and the growing body of evidence surrounding morbidity in late-stage melanoma, it is essential that QoL be included in assessing the benefits of early detection.
Sections du résumé
Background
UNASSIGNED
The morbidity associated with advanced stage melanoma is an important consideration in the dialog surrounding early detection and overdiagnosis. Few studies have stratified melanoma patient quality of life (QoL) by stage at diagnosis.
Objective
UNASSIGNED
We sought to investigate if melanoma stage is independently associated with changes in QoL within a large, community-based melanoma registry. Secondarily, we investigated whether demographic factors such as age, geographic location or level of education are associated with changes in QoL in the same population.
Methods
UNASSIGNED
1108 melanoma patients were surveyed over a three-month period using the QoL in Adult Cancer Survivors Survey, consisting of 47 items on a 7-point frequency scale. Data were analysed using both descriptive statistical models and adjusted multivariate logistic regression.
Results
UNASSIGNED
There were 677 respondents generating a 61% response rate. Overall, higher stage at diagnosis correlated with the largest decreases in QoL as it pertained to both general (
Conclusion
UNASSIGNED
Earlier stage at melanoma diagnosis is associated with better QoL and thus represents a crucial intervention in patient care. Given our findings and the growing body of evidence surrounding morbidity in late-stage melanoma, it is essential that QoL be included in assessing the benefits of early detection.
Identifiants
pubmed: 37538330
doi: 10.1002/ski2.237
pii: SKI2237
pmc: PMC10395626
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e237Informations de copyright
© 2023 The Authors. Skin Health and Disease published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
JAMA Oncol. 2022 May 1;8(5):755-759
pubmed: 35323844
JAMA Dermatol. 2022 May 1;158(5):485-487
pubmed: 35385059
Melanoma Res. 2015 Apr;25(2):157-63
pubmed: 25647736
BMJ Open. 2015 Sep 15;5(9):e008158
pubmed: 26373399
JAMA Dermatol. 2019 Aug 01;155(8):899-905
pubmed: 31215975
Cancer. 2020 Feb 1;126(3):611-618
pubmed: 31639198
Clin Cancer Res. 2017 Oct 1;23(19):5661-5665
pubmed: 28179454
Lancet Oncol. 2021 May;22(5):655-664
pubmed: 33857414
JAMA Dermatol. 2022 Jun 1;158(6):675-679
pubmed: 35442415
Asia Pac J Clin Oncol. 2021 Aug;17(4):359-367
pubmed: 33567163
Br J Cancer. 2012 Feb 28;106(5):970-4
pubmed: 22294187
Eur J Cancer. 2021 Jul;152:116-128
pubmed: 34091420
J Natl Cancer Inst. 2010 May 5;102(9):605-13
pubmed: 20413742
Qual Life Res. 2015 Jan;24(1):205-12
pubmed: 24996392
J Dtsch Dermatol Ges. 2020 Nov;18(11):1236-1243
pubmed: 32841508
JAMA Dermatol. 2018 Apr 1;154(4):398-399
pubmed: 29466567
JAMA Dermatol. 2022 May 1;158(5):483-485
pubmed: 35385064
Cochrane Database Syst Rev. 2018 Feb 06;2:CD011123
pubmed: 29405038
Cancer. 2008 Dec 15;113(12):3459-66
pubmed: 18988231
Int J Womens Dermatol. 2018 Jun 11;4(3):119-121
pubmed: 30175212
BMJ. 2017 Jun 28;357:j2813
pubmed: 28659278
Cancer Med. 2021 Nov;10(21):7457-7465
pubmed: 34647433
J Am Acad Dermatol. 2018 Nov;79(5):884-891.e3
pubmed: 30057360
Dermatol Online J. 2021 Apr 15;27(4):
pubmed: 33999590
J Am Acad Dermatol. 2021 Oct;85(4):841-846
pubmed: 34116095
Qual Life Res. 2014 Mar;23(2):585-92
pubmed: 23881516
Acta Derm Venereol. 2021 Aug 25;101(8):adv00525
pubmed: 34396424
J Cutan Pathol. 2012 Jan;39(1):9-16
pubmed: 22211330
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
JAMA Dermatol. 2022 May 1;158(5):504-512
pubmed: 35385051
Ann Oncol. 1995 Nov;6(9):858
pubmed: 8624285
J Am Acad Dermatol. 2017 Jan;76(1):129-139.e10
pubmed: 27707591
JAMA Dermatol. 2022 Apr 1;158(4):426-431
pubmed: 35293957
Skin Health Dis. 2023 Apr 17;3(4):e237
pubmed: 37538330
Qual Life Res. 2005 May;14(4):1007-23
pubmed: 16041897
Int J Cancer. 2010 Jan 15;126(2):450-8
pubmed: 19609948
Eur J Cancer. 2016 Jan;53:33-41
pubmed: 26693897
Int J Cancer. 1999 Oct 29;83(3):314-7
pubmed: 10495422
Cancers (Basel). 2021 Dec 02;13(23):
pubmed: 34885180
J Invest Dermatol. 2019 Jan;139(1):25-30
pubmed: 30482597
J Am Acad Dermatol. 2020 Jul;83(1):e83-e84
pubmed: 32380217
Front Public Health. 2021 Feb 22;9:630620
pubmed: 33692982
Aust J Gen Pract. 2021 Jan 22;50:
pubmed: 33543153
JAMA Intern Med. 2017 Jul 1;177(7):915-916
pubmed: 28492850
Melanoma Res. 2018 Apr;28(2):134-142
pubmed: 29261570
Telemed J E Health. 2019 Nov;25(11):1022-1032
pubmed: 30741608
JAMA Dermatol. 2022 Sep 1;158(9):1083-1084
pubmed: 35895049
J Am Acad Dermatol. 2021 Aug;85(2):486-489
pubmed: 29906543
Pigment Cell Melanoma Res. 2017 Jan;30(6):511-520
pubmed: 28950054
Dermatol Clin. 2012 Jan;30(1):53-9, viii
pubmed: 22117867
PLoS One. 2015 Jan 23;10(1):e0116440
pubmed: 25615573
JAMA. 2016 Jul 26;316(4):429-35
pubmed: 27458948
JAMA Dermatol. 2022 Sep 1;158(9):1082-1083
pubmed: 35895044